
    
      At Inclusion Visit (Visit 2 [within 72 hours after acute MI]), subjects will be randomly
      assigned to 1 of the following 3 treatment groups in a 1:1:1 ratio:

        -  Group 1: Subjects will receive 50 mg firibastat BID for 2 weeks and then 100 mg BID for
           10 weeks

        -  Group 2: Subjects will receive 250 mg firibastat BID for 2 weeks and then 500 mg BID for
           10 weeks

        -  Group 3: Subjects will receive 2.5 mg ramipril BID for 2 weeks and then 5 mg BID for 10
           weeks

      Then subjects will undergo study procedures at Titration Visit (Visit 3 [Day 14]), Treatment
      Visit (Visit 4 Day 42]) and End-of-Treatment Visit (Visit 5 [Day 84]).
    
  